Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes
Gevaert AB, Tibebu S, Mamas MA, Ravindra NG, Lee SF, Ahmad T, Ko DT, Januzzi JL, Van Spall HGC. Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Failure 2021, 8: 2741-2754. PMID: 33934542, PMCID: PMC8318507, DOI: 10.1002/ehf2.13344.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionChronic obstructive pulmonary diseaseHazard ratioComposite outcomePrimary outcomeAtrial fibrillationHeart diseaseComposite cardiovascular deathEjection fraction categoriesSecondary composite outcomeHeart failure outcomesPrimary composite outcomeObstructive pulmonary diseaseVentricular ejection fractionValvular heart diseaseCoronary heart diseaseGreater prognostic informationDifferent risk categoriesCause deathHF rehospitalizationPredominant comorbiditiesCardiovascular deathHF trialsBaseline characteristicsSecondary outcomesCLINICAL PHENOGROUPS ARE MORE EFFECTIVE THAN LEFT VENTRICULAR EJECTION FRACTION CATEGORIES IN STRATIFYING HEART FAILURE OUTCOMES
Gevaert A, Tibebu S, Mamas M, Ravindra N, Lee S, Ahmad T, Ko D, Januzzi J, Van Spall H. CLINICAL PHENOGROUPS ARE MORE EFFECTIVE THAN LEFT VENTRICULAR EJECTION FRACTION CATEGORIES IN STRATIFYING HEART FAILURE OUTCOMES. Journal Of The American College Of Cardiology 2021, 77: 587. DOI: 10.1016/s0735-1097(21)01946-x.Peer-Reviewed Original ResearchTrends in 30- and 90-Day Readmission Rates for Heart Failure
Khan MS, Sreenivasan J, Lateef N, Abougergi MS, Greene SJ, Ahmad T, Anker SD, Fonarow GC, Butler J. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circulation Heart Failure 2021, 14: e008335. PMID: 33866827, DOI: 10.1161/circheartfailure.121.008335.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramHF readmission ratesIndex HF hospitalizationLow-volume hospitalsReadmission ratesHF hospitalizationPayer sourceHeart failure outcomesNational Readmission DatabaseReadmissions Reduction ProgramNon-Medicare insuranceCause 30Cause readmissionEjection fractionHeart failureSubgroup analysisReadmissionLinear regression analysisPrimary analysisSecondary analysisHospitalizationFailure outcomesHF volumeLimited dataRegression analysisEffects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial